索尔克研究所欢迎风险投资家兼发明家安德鲁·塞尼（Andrew Senyei）加入其董事会

2025 年 12 月 15 日

索尔克研究所欢迎风险投资家兼发明家安德鲁·塞尼（Andrew Senyei）加入其董事会

2025 年 12 月 15 日

拉霍亚—医师、发明家和风险投资家安德鲁·“德鲁”·森耶伊（医学博士）已被新任命为索尔克研究所的 理事会. 他将与来自世界各地的商业和非营利组织领导人合作，共同推进索尔克研究所的基础和创新生物学研究。.

Senyei has worked in the healthcare and emerging technology industries for over 30 years and is credited with more than 30 patents and 45 peer-reviewed publications. He has also served on the boards of more than 30 private and public companies.

“Drew understands the value of early-stage science and has been critical to the development of numerous cutting-edge medical technologies,” says Salk President 杰拉尔德·乔伊斯, MD, PhD. “His wealth of experience advising scientific institutions will be a great resource to us, and we look forward to working with him.”

Senyei earned his medical degree at Northwestern University and completed his residency training at the University of California, Irvine, where he served on the faculty before cofounding Enterprise Partners Venture Capital in 1986. The firm invested in early-stage disruptive technologies and services in healthcare, biotechnology, and information technology. He continues to be active in early-stage technology investing and is now a senior advisor to private equity fund Healthpoint Capital.

Early in his career, Senyei invented the first FDA-approved test to predict preterm birth, which has now been used by more than 8 million women worldwide. He was also the founding investor of Nuvasive, one of the largest orthopedic companies in the US, until it was acquired by Globus Medical in 2023. Senyei served as executive chairman of NeoSeq Ltd., a company specializing in advanced genetic testing for cancer and other diseases. He is a life trustee for Northwestern University, former chair of the UC San Diego Jacobs School of Engineering Advisory Council, and a current member of the UC San Diego Foundation Board.

“Salk’s long-standing tradition of world-class, curiosity-driven basic biological research has consistently produced transformative discoveries, many of which began as unexpected findings and became the basis for new ways to prevent and treat disease. I am honored to join the board and assist in translating this extraordinary science into real-world impact,” Senyei says.